oche (RHHBY) is being investigated by Romanian authorities for allegedly pursuing anticompetitive practices, the latest instance in which a large drug maker is probed by a European government for such behavior.

The company is suspected of having sold cancer medicines to its distributors at higher wholesale prices than the prices offered by its own subsidiary when bidding for hospital business. The other probe involves allegedly attempting to thwart a generic version of its Tarceva cancer drug from reaching the market.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.